Evaxion Biotech A/S (NASDAQ:EVAX) Posts Earnings Results, Beats Expectations By $0.19 EPS

Evaxion Biotech A/S (NASDAQ:EVAX) released its quarterly earnings results on Tuesday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.19, Zacks reports. The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $1.66 million.

Evaxion Biotech A/S Trading Up 1.8 %

Shares of EVAX stock opened at $1.69 on Thursday. The company has a market capitalization of $1.98 million, a P/E ratio of -1.17 and a beta of -0.25. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The business’s 50 day moving average is $2.43 and its two-hundred day moving average is $6.94. Evaxion Biotech A/S has a twelve month low of $1.61 and a twelve month high of $22.05.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a report on Wednesday. Lake Street Capital lowered their price objective on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.